Convective heat system shows efficacy in treating BPH
MR image analyses show near complete lesion resolution at 6 months
Stockholm, Sweden—Analyses of serial magnetic resonance imaging and three-dimensional renderings of those images provide proof of principle for using convective thermal heating to ablate prostate tissue, and early evidence suggests the efficacy and potential clinical advantages of using this novel technology to treat BPH, said first author Lance A. Mynderse, MD, at the European Association of Urology annual congress in Stockholm, Sweden.
The RezÅ«m convective water vapor system (NxThera, Inc., Maple Grove, MN), which has received the CE mark to treat BPH, is an office-based transurethral treatment and delivers steam to tissue in the transition zone of the prostate. Tissue ablation results from phase-change, convective thermal energy transfer. When the steam condenses, it releases stored thermal energy (540 calories/mL of water) that denatures tissue cell membranes and causes cellular necrosis.
The investigation included 60 men treated at three centers who underwent the vapor treatment with between one and three injections per lateral lobe of the prostate, and also included treatment of the median lobe, if present. Gadolinium-enhanced MRIs were performed after 1 week and at 1, 3, and 6 months.